

Opto Circuits subsidiary receives US FDA approval on Sequel™, a next generation pulse oximeter module

Waukesha, WI, USA | Bengaluru, India | 1st June 2009

Opto Circuits (India) Limited (OCI), India's leading manufacturer of medical diagnostics and interventional products, announced the receipt of US FDA approval on a next-generation pulse oximeter (SpO₂) module, Sequel™ developed by its Waukesha-based subsidiary - Criticare Systems, Inc. (CSI). The approval enables immediate integration of the module into CSI monitors and marketing and sale of the product to OEM manufacturers across the globe.

Sequel™ is a miniaturized, motion-tolerant and a more sensitive SpO₂ module that is designed to power new generation vital signs monitors and other patient monitors for the entire CSI range of products. This product is also a perfect fit for OEM systems integrators.

Sequel™ demonstrates better accuracies and is equally adaptable through neonates to adults. It is also one of the lowest power consumption modules.

Pulse oximetry (detection of arterial oxygen saturation and heart beat rate) is one of the five 'vital signs' that are monitored on a patient. Continuous oxygenation monitoring in hospitals and other critical care settings is now a standard of care.